Cost-Effectiveness Analysis of Antihypertensive Combination Drugs in Hospitalized Patients at Kendari City Hospital for the Period 2023

DOI

10.2991/978-94-6463-890-5_21How to use a DOI?

Keywords

Cost Effectiveness; Combination Antihypertensives; Hypertension

Abstract

Hypertension is a non-communicable disease and one of the leading causes of premature death worldwide. It is characterized by blood pressure readings with systolic and diastolic values ≥ 140/90 mmHg. Rising treatment costs increase the financial burden and reduce access to quality health services. To address these issues, a cost-effectiveness analysis is needed, involving the calculation of direct medical costs as well as ACER and ICER values. This study aims to evaluate the cost-effectiveness of antihypertensive combination drugs for inpatients at Kendari City Hospital during the 2023 period. This study used a non-experimental quantitative method with a cross sectional research design, retrospectively collecting data on medical record data of hospitalized hypertensive patients who used a combination of two drugs, obtained 54 samples. The effectiveness of therapy is measured based on a decrease in systolic diastolic blood pressure and length of stay, while cost effectiveness is seen based on ACER and ICER values. The results showed that the average total direct medical costs of the Amlodipine-Candesartan drug combination were the lowest at Rp 12,846,753 compared to Furosemide-Candesartan. The effectiveness of the Amlodipine-Candesartan drug combination therapy was more at 85% with an average length of stay of 4.9 days and the Furosemide-Candesartan drug combination was 62% with an average length of stay of 6.1 days, the results of the t test test average value (p-value < 0.005) there was a significant difference. The cost-effectiveness of the Amlodipine-Candesartan combination is more cost-effective based on systolic diastolic blood pressure with an ACER value of Rp. 151,138 and an ICER value of -Rp.236,369. Compared to the Furosemide-Candesartan combination. The conclusion of this study is based on the results of the study that Amlodipine-Candesartan antihypertensive combination therapy is the most cost effective therapy.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Herlina Arya Putri Edison
AU  - Ruslan Majid
AU  - Adryan</gi> Fristiohady
AU  - Eka Fitrotu Syifa
PY  - 2025
DA  - 2025/11/17
TI  - Cost-Effectiveness Analysis of Antihypertensive Combination Drugs in Hospitalized Patients at Kendari City Hospital for the Period 2023
BT  - Proceedings of the 2nd Halu Oleo International Conference on Public Health (HOICPH 2024)
PB  - Atlantis Press
SP  - 210
EP  - 218
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-890-5_21
DO  - 10.2991/978-94-6463-890-5_21
ID  - Edison2025
ER  -